Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Therapeutics
100,0
%
| 108 | 100,0 % | 331 | 100,0 % | +204,74% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 108 | 100,0 % | 331 | 100,0 % | +204,74% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Alexander Schuth
FOU | Founder | 50 | 14-10-13 |
Ryan Watts
FOU | Founder | 48 | 14-10-13 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-20 |
Dana Andersen
CTO | Chief Tech/Sci/R&D Officer | - | 07-08-18 |
Carole Ho
CTO | Chief Tech/Sci/R&D Officer | 51 | 01-06-15 |
Steve Krognes
BRD | Director/Board Member | 56 | 01-10-15 |
Laura G. Hansen
IRC | Investor Relations Contact | - | - |
Katie Peng
PRN | Corporate Officer/Principal | - | 27-09-21 |
Erica Kratz
LAW | General Counsel | - | - |
Chris Walsh
LAW | General Counsel | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Vicki Sato
CHM | Chairman | 75 | 01-04-15 |
Jay Flatley
BRD | Director/Board Member | 71 | 01-04-15 |
David Schenkein
BRD | Director/Board Member | 66 | 01-04-15 |
Founder | 64 | 14-10-13 | |
Jennifer Cook
BRD | Director/Board Member | 58 | 06-11-18 |
Peter Klein
BRD | Director/Board Member | 61 | 16-03-18 |
Erik Harris
BRD | Director/Board Member | 54 | 07-02-22 |
Steve Krognes
BRD | Director/Board Member | 56 | 01-10-15 |
Nancy Thornberry
BRD | Director/Board Member | 67 | 08-01-21 |
Ryan Watts
FOU | Founder | 48 | 14-10-13 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 142 609 036 | 123 102 227 ( 86,32 %) | 0 | 86,32 % |
Bedrijfsgegevens
Denali Therapeutics, Inc.
161 Oyster Point Boulevard
94080, San Francisco
+650 866 8548
http://www.denalitherapeutics.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,66% | 111 mld. | |
+11,23% | 105 mld. | |
-2,82% | 21,93 mld. | |
-12,15% | 22,34 mld. | |
-5,52% | 18,59 mld. | |
-36,52% | 18,12 mld. | |
-10,09% | 16,96 mld. | |
+3,33% | 13,7 mld. | |
+36,58% | 12,45 mld. |